Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab in primary metastatic nasopharyngeal carcinoma
NCT04517214Phase 2Active, not recruiting
- Sponsor
- Fudan University
- Start
- Nov 2020
- Primary completion
- Dec 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in nasopharyngeal carcinoma (NPC), sponsored by Fudan University. Started Nov 2020; status: active, not recruiting.
02
Drugs
toripalimab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT04517214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04517214.